Nastya Kharlamova

749 total citations
16 papers, 545 citations indexed

About

Nastya Kharlamova is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Periodontics. According to data from OpenAlex, Nastya Kharlamova has authored 16 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 10 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Periodontics. Recurrent topics in Nastya Kharlamova's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Systemic Lupus Erythematosus Research (5 papers). Nastya Kharlamova is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Systemic Lupus Erythematosus Research (5 papers). Nastya Kharlamova collaborates with scholars based in Sweden, Poland and United Kingdom. Nastya Kharlamova's co-authors include Karin Lundberg, Lena Israelsson, Lars Alfredsson, Xia Jiang, Natalia Sherina, Barbara Potempa, Jan Potempa, Evan Reed, Nicky Dunn and Anna Fogdell‐Hahn and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Nastya Kharlamova

14 papers receiving 540 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nastya Kharlamova Sweden 12 351 173 125 109 57 16 545
Muslima Chowdhury United Kingdom 5 258 0.7× 51 0.3× 120 1.0× 142 1.3× 60 1.1× 7 395
G. Illei United States 6 174 0.5× 28 0.2× 72 0.6× 145 1.3× 81 1.4× 13 413
Júlia Spengler United Kingdom 5 105 0.3× 37 0.2× 63 0.5× 189 1.7× 93 1.6× 8 339
M Fife United Kingdom 10 128 0.4× 47 0.3× 16 0.1× 253 2.3× 151 2.6× 11 527
JP Callen United States 13 159 0.5× 38 0.2× 40 0.3× 52 0.5× 16 0.3× 29 387
Carolijn Smids Netherlands 10 257 0.7× 172 1.0× 6 0.0× 180 1.7× 53 0.9× 14 603
Keita Kobayashi Japan 15 42 0.1× 37 0.2× 37 0.3× 83 0.8× 130 2.3× 73 659
Johannes Schulte-Pelkum Germany 8 188 0.5× 94 0.5× 6 0.0× 118 1.1× 51 0.9× 14 371
Igor Snast Israel 11 148 0.4× 15 0.1× 14 0.1× 158 1.4× 44 0.8× 41 555
Manuel Almagro Spain 13 73 0.2× 13 0.1× 24 0.2× 73 0.7× 61 1.1× 49 473

Countries citing papers authored by Nastya Kharlamova

Since Specialization
Citations

This map shows the geographic impact of Nastya Kharlamova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nastya Kharlamova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nastya Kharlamova more than expected).

Fields of papers citing papers by Nastya Kharlamova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nastya Kharlamova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nastya Kharlamova. The network helps show where Nastya Kharlamova may publish in the future.

Co-authorship network of co-authors of Nastya Kharlamova

This figure shows the co-authorship network connecting the top 25 collaborators of Nastya Kharlamova. A scholar is included among the top collaborators of Nastya Kharlamova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nastya Kharlamova. Nastya Kharlamova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Wincup, Chris, Nicky Dunn, Ali Manouchehrinia, et al.. (2022). Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus. Lara D. Veeken. 62(7). 2601–2610. 15 indexed citations
3.
Faustini, Francesca, Nicky Dunn, Nastya Kharlamova, et al.. (2021). First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. Arthritis Research & Therapy. 23(1). 211–211. 16 indexed citations
4.
Tar, Ildikó, Éva Csősz, Edit Végh, et al.. (2021). Salivary citrullinated proteins in rheumatoid arthritis and associated periodontal disease. Scientific Reports. 11(1). 13525–13525. 20 indexed citations
5.
Kharlamova, Nastya, Nicky Dunn, Sahl Khalid Bedri, et al.. (2021). False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases. Frontiers in Immunology. 12. 666114–666114. 19 indexed citations
6.
Kharlamova, Nastya, Nicky Dunn, Malin Ryner, et al.. (2020). Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier. Frontiers in Immunology. 11. 1365–1365. 18 indexed citations
7.
Dunn, Nicky, Nastya Kharlamova, & Anna Fogdell‐Hahn. (2020). The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy. Scandinavian Journal of Immunology. 92(6). e12984–e12984. 24 indexed citations
8.
Sherina, Natalia, Natalie Sippl, Lena Israelsson, et al.. (2019). P042/O05 Molecular mimicry and autoimmunity: anti-P.gingivalis antibody response in ACPA-positive rheumatoid arthritis. Annals of the Rheumatic Diseases. 78. A16–A17.
9.
Eriksson, Kaja, Erik Lönnblom, Piotr Mydel, et al.. (2016). Effects by periodontitis on pristane-induced arthritis in rats. Journal of Translational Medicine. 14(1). 311–311. 14 indexed citations
10.
Reed, Evan, Xia Jiang, Nastya Kharlamova, et al.. (2016). Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies. Arthritis Research & Therapy. 18(1). 96–96. 53 indexed citations
11.
Jiang, Xia, Nastya Kharlamova, Lena Israelsson, et al.. (2016). A2.11 Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies. Annals of the Rheumatic Diseases. 75. A19–A19. 1 indexed citations
12.
Johansson, Linda, Natalia Sherina, Nastya Kharlamova, et al.. (2016). Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis. Arthritis Research & Therapy. 18(1). 201–201. 81 indexed citations
13.
Kharlamova, Nastya, Xia Jiang, Natalia Sherina, et al.. (2015). Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology. Arthritis & Rheumatology. 68(3). 604–613. 121 indexed citations
14.
Kharlamova, Nastya, Natalia Sherina, Lena Israelsson, et al.. (2014). A6.8 Elevated antibody levels to porphyromonas gingivalis detected in rheumatoid arthritis patients with a specific anti-citrullinated protein/peptide antibody profile. Annals of the Rheumatic Diseases. 73. A73–A74. 2 indexed citations
15.
Ossipova, Elena, Evan Reed, Nastya Kharlamova, et al.. (2014). Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis Research & Therapy. 16(4). R167–R167. 37 indexed citations
16.
Lundberg, Karin, Camilla Bengtsson, Nastya Kharlamova, et al.. (2012). Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Annals of the Rheumatic Diseases. 72(5). 652–658. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Muslima Chowdhury Breakdown of academic impact, for papers by G. Illei Breakdown of academic impact, for papers by Júlia Spengler Breakdown of academic impact, for papers by M Fife Breakdown of academic impact, for papers by JP Callen Breakdown of academic impact, for papers by Carolijn Smids Breakdown of academic impact, for papers by Keita Kobayashi Breakdown of academic impact, for papers by Johannes Schulte-Pelkum Breakdown of academic impact, for papers by Igor Snast Breakdown of academic impact, for papers by Manuel Almagro
Rankless by CCL
2026